Edition:
India

Spark Therapeutics Inc (ONCE.OQ)

ONCE.OQ on NASDAQ Stock Exchange Global Select Market

47.76USD
19 Oct 2018
Change (% chg)

$-2.11 (-4.23%)
Prev Close
$49.87
Open
$49.87
Day's High
$50.94
Day's Low
$47.39
Volume
129,453
Avg. Vol
198,747
52-wk High
$96.51
52-wk Low
$41.06

Summary

Name Age Since Current Position

Steven Altschuler

64 2013 Independent Chairman of the Board

Katherine High

66 2017 President, Head of Research and Development and Director

Jeffrey Marrazzo

39 2016 Chief Executive Officer, Co-Founder, Director

Stephen Webster

57 2014 Chief Financial Officer

John Furey

53 2016 Chief Operating Officer

Lisa Dalton

45 2018 Chief Human Resource Officer

Federico Mingozzi

44 2017 Chief Scientific Officer

Daniel Faga

38 2016 Chief Business Officer

Joseph La Barge

46 2017 Chief Legal Officer

Lars Ekman

68 2014 Independent Director

Anand Mehra

42 2014 Independent Director

Vincent Milano

54 2014 Independent Director

Robert Perez

53 2018 Independent Director

Elliot Sigal

66 2014 Independent Director

Lota Zoth

58 2016 Independent Director

Biographies

Name Description

Steven Altschuler

Dr. Steven M. Altschuler, M.D. is Independent Chairman of the Board of Spark Therapeutics, Inc. Dr. Altschuler became Senior Vice President of Health Affairs at the University of Miami and Chief Executive Officer of UHealth-University of Miami Health System in January 2016. Previously, he was Chief Executive Officer of CHOP and The Children’s Hospital of Philadelphia Foundation, or the CHOP Foundation, from 2000 to 2015. Prior to serving as the Chief Executive Officer of CHOP, Dr. Altschuler served in many leadership roles at CHOP including: Division Chief of Gastroenterology, Physician-in-Chief, inaugural holder of the Leonard and Madlyn Abramson Endowed Chair in Pediatrics and Professor and Chair of the Department of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania, where he was a faculty member from 1985 to 2000. Dr. Altschuler has served on the board of directors for Mead Johnson Nutrition Company since 2009 and Weight Watchers International since 2012. Dr. Altschuler holds a B.A. in mathematics and an M.D., both from Case Western Reserve University. He completed his pediatric internship and residency at Children’s Hospital Medical Center-Boston and fellowship training in gastroenterology and nutrition at CHOP and the University of Pennsylvania School of Medicine.

Katherine High

Dr. Katherine A. High, M.D. is President, Head of Research and Development and Director of the company. From September 2014 through September 2017, she served as the President, Chief Scientific Officer, Director of Spark Therapeutics, Inc. Prior to serving as our President, Dr. High provided advice to Spark and subsequently served as an independent consultant to Spark from December 2013 to September 2014. Dr. High was previously a Professor at the Perelman School of Medicine at the University of Pennsylvania and an Investigator of the Howard Hughes Medical Institute. She served as the Director of the Center for Cellular and Molecular Therapeutics at CHOP from 2004 to 2014, where her team’s research led to the discovery of new gene and cell therapies for genetic diseases. Dr. High began her independent research career at Yale University and the University of North Carolina studying the molecular basis of blood coagulation and the development of novel therapeutics for the treatment of bleeding disorders. Dr. High’s studies at CHOP established the first proof of principle of gene therapy for hemophilia in preclinical models and led to a series of studies that characterized the human immune response to AAV vectors in a variety of target tissues. Dr. High served a five-year term from 2000 to 2005 on the FDA Advisory Committee on Cell, Tissue and Gene Therapies and is a past-president of the American Society of Gene & Cell Therapy. Dr. High holds an A.B. in chemistry from Harvard, an M.D. from the University of North Carolina School of Medicine, a business certification from the University of North Carolina Business School Management Institute for Hospital Administrators and an honorary M.A. from the University of Pennsylvania.

Jeffrey Marrazzo

Mr. Jeffrey D. Marrazzo is Chief Executive Officer, Co-Founder, Director of Spark Therapeutics, Inc. Prior to founding Spark, Mr. Marrazzo launched and was Chief Business Officer of the U.S. division of Molecular Health, Inc. from 2011 to 2013. Mr. Marrazzo was part of the founding management of Generation Health from 2009 to 2011, up to and through the acquisition of a majority of the company’s shares by CVS Caremark. From 2008 to 2009, Mr. Marrazzo served as an employee and independent consultant to the business development and finance teams at Tengion Inc. and, from 2011 to 2013, Mr. Marrazzo served as an independent consultant to the Children's Hospital of Philadelphia, or CHOP. Previously, Mr. Marrazzo served as healthcare advisor to former Pennsylvania Governor Edward G. Rendell and as an IBM management consultant to global pharmaceutical companies. Mr. Marrazzo holds a B.S.E. and B.A. in systems science and engineering and economics from the University of Pennsylvania and a dual M.B.A./M.P.A. from The Wharton School and Harvard University.

Stephen Webster

Mr. Stephen W. Webster is Chief Financial Officer of Spark Therapeutics, Inc. From June 2012 to November 2013, he served as Senior Vice President, Finance and Chief Financial Officer at Optimer Pharmaceuticals. From June 2008 to December 2011, Mr. Webster served as Senior Vice President, Finance and Chief Financial Officer at Adolor Corporation. Mr. Webster has served on the Board of Directors of Viking Therapeutics Inc. since June 2014. Mr. Webster holds an A.B. in economics from Dartmouth College and an M.B.A. in finance from The Wharton School at the University of Pennsylvania.

John Furey

Mr. John Furey is Chief Operating Officer of the Company. He was Senior Vice President and Head of Global Operations of Baxalta Incorporated beginning upon Baxalta’s separation from Baxter International Inc. in July 2015 until July 2016. Mr. Furey previously served as Head of Global Operations for Baxter International Inc. from October 2014 to July 2015 and as Global Franchise Head, Vaccines from February 2013 to September 2015. Prior to Baxter International Inc. Mr. Furey served as General Manager for Vaccines in China for Pfizer from April 2011 to January 2013. Prior to that, Mr. Furey spent 20 years with Wyeth and Pfizer, holding roles of increasing responsibility within the biotech and vaccines divisions, and various leadership roles in commercial, product supply and manufacturing operations. Early in his career he was an engineering manager at Analog Devices and served as a Scientific Officer with Ireland’s National Scientific Agency. Mr. Furey holds a B.Sc. in environmental health from Trinity College Dublin and a MBA from St Joseph's University.

Lisa Dalton

Ms. Lisa Dalton is the Chief Human Resource Officer of the company. she served as Head - Human Resources of Spark Therapeutics, Inc. Prior to joining Spark, Ms. Dalton served as Vice President, Human Resources at Shire Pharmaceutical, where she most recently led human resources merger and acquisition activity and implementation. Ms. Dalton also has held roles in compensation and human resources business partnering with Franklin Templeton and Applied Biosystems. Ms. Dalton holds a B.A. in psychology from Penn State University and an M.B.A. from Rutgers University School of Business.

Federico Mingozzi

Dr. Federico Mingozzi Ph.D., is Chief Scientific Officer of the company. He joins Spark Therapeutics from the French National Institute of Health and Medical Research (INSERM) and Genethon, a leading French nonprofit R&D organization focused on rare diseases, where he led the development of liver-targeted gene therapies for inherited diseases such as Crigler-Najjar syndrome, and worked on the characterization of immunity and tolerance in gene transfer. He serves as faculty at the Pierre and Marie Curie University in Paris and Universitat Autonoma de Barcelona, Spain. Dr. Mingozzi has had a distinguished career in gene therapy research, including earlier as director of translational research, Center for Cellular and Molecular Therapeutics, at Children's Hospital of Philadelphia, where he was involved in the development of gene therapies based on the AAV vector platform.

Daniel Faga

Mr. Daniel R. Faga is Chief Business Officer of the Company. From 2009-2016, Mr. Faga was a Managing Director at Centerview Partners, where he had served as a founding member of Centerview's healthcare advisory practice. Primarily focused in the life sciences sector, Mr. Faga has deep expertise in corporate strategy, M&A and partnering, including advising on more than $50 billion in biopharma transactions. Prior to Centerview, Mr. Faga worked at Merrill Lynch in its healthcare investment banking group and as a management consultant in the Life Sciences Practice at PRTM. Mr. Faga earned a B.S. in Engineering from Cornell University and an M.B.A. in Health Care Management from The Wharton School at the University of Pennsylvania.

Joseph La Barge

Mr. Joseph W. La Barge, Esq. is Chief Legal Officer of the company. he served as General Counsel of Spark Therapeutics, Inc. Prior to joining Spark, Mr. La Barge was of counsel at Ballard Spahr LLP from April 2012 to April 2013, where he advised biotechnology companies in private and public financings, mergers and acquisitions and collaboration and licensing transactions. He also served as the Deputy General Counsel to the Kennedy Health System from April 2013 to November 2013. Mr. La Barge was the Vice President,

Lars Ekman

Dr. Lars G. Ekman, M.D., Ph.D. is Independent Director of Spark Therapeutics, Inc. He is currently Executive Partner at Sofinnova Ventures which he joined in 2008. Prior to joining Sofinnova Ventures, Dr. Ekman was President of Research and Development at Elan Corporation (now Perrigo) from January 2001 to December 2007. Prior to Elan, he was Executive Vice President, Research and Development, at Schwarz Pharma AG (now UCB) and, prior to then, held a variety of senior scientific and clinical roles at Pharmacia (now Pfizer). Dr. Ekman is Chairman of Amarin Corporation, Chairman of Prothena Biosciences and Chairman of Sophiris Bioscience. He also serves on the board of directors of Ultragenyx. He co-founded and served as Chief Executive Officer of Cebix, Inc., and served on its board from 2009 to 2015 as well as on the board of directors of InterMune, Inc. from 2006-2015, Elan Plc from 2005-2013 and Ocera Therapeutics, Inc. from 2009-2015. Dr. Ekman is a board-certified surgeon and holds an M.D. and a Ph.D. in experimental biology from the University of Gothenburg, Sweden.

Anand Mehra

Dr. Anand Mehra, M.D. is Independent Director of Spark Therapeutics, Inc. Dr. Mehra is currently a General Partner of Sofinnova Ventures, which he joined in 2007. Prior to joining Sofinnova, Dr. Mehra worked in J.P. Morgan’s private equity and venture capital group, and before that, Dr. Mehra was a consultant in McKinsey & Company’s pharmaceutical practice. Dr. Mehra has served on the board of directors of Aerie Pharmaceuticals since August 2010, Aclaris Therapeutics, Inc. since 2014 and Marinus Pharmaceuticals since October 2007 as well as several private companies. Dr. Mehra holds a B.A. from the University of Virginia and an M.D. from Columbia University’s College of Physicians and Surgeons.

Vincent Milano

Mr. Vincent J. Milano is Independent Director of Spark Therapeutics, Inc. Mr. Milano is currently the Chief Executive Officer of Idera Pharmaceuticals Inc. Prior to joining Idera, Mr. Milano served as President, Chief Executive Officer and Chairman of the board of directors of ViroPharma Incorporated, or ViroPharma, from 2008 to 2014, which was acquired by Shire Pharmaceuticals in January 2014. Mr. Milano joined ViroPharma in 1996 and served as Vice President, Chief Financial Officer and Treasurer from 1997 to 2006. Prior to joining ViroPharma, Mr. Milano served as a Senior Manager at KPMG LLP, independent certified public accountants. Mr. Milano has served on the board of directors of Vanda Pharmaceuticals since 2010 and the board of directors of VenatoRx, a privately held biotechnology company, since 2013. He also serves on the board of directors of Pennsylvania Bio. Mr. Milano holds a B.S. in accounting from Rider College.

Robert Perez

Mr. Robert J. Perez is independent Director of the Company. Mr. Perez has been the founder and managing partner of Vineyard Sound Advisors since 2015, providing advisory services to companies in the biopharmaceutical industry, and is the founder and chairman of Life Science Cares, a nonprofit organization focused on fighting poverty in the greater Boston area. He previously served as the chief executive officer of Cubist Pharmaceuticals, Inc. until its acquisition by Merck in 2015. Prior to his tenure as Cubist's CEO, Mr. Perez held multiple roles since joining the company in 2003, including president, chief operating officer and senior vice president of sales and marketing, where he oversaw the launch of Cubicin (daptomycin for injection). He also held roles of varying commercial responsibilities in the industry, specifically leading Biogen's central nervous system (CNS) commercial organization and as a regional business director at Zeneca Pharmaceuticals. He currently serves on the boards of directors at several public and private companies.

Elliot Sigal

Dr. Elliott Sigel M.D. Ph.D. is Independent Director of Spark Therapeutics, Inc. Dr. Sigal served as Chief Scientific Officer of Bristol-Myers Squibb (BMS) from 2004 until his retirement in 2013 and was a member of the board of directors from 2011 to 2013. Dr. Sigal joined BMS in 1997 and held positions of increasing responsibility in drug discovery and development and was a member of the executive committee from 2001-2013. Prior to BMS, he was Vice President of R&D and Chief Executive Officer for the genomics firm Mercator Genetics Inc. Dr. Sigal currently serves as a member of the board of directors for Adaptimmune Therapeutics plc and the Mead Johnson Nutrition Company. In addition, Dr. Sigal is an advisor to the life sciences venture firm, New Enterprise Associates, and consults for select biopharmaceutical companies. Dr. Sigal holds B.S., M.S. and Ph.D. degrees in industrial engineering from Purdue University and an M.D. from the University of Chicago. He completed his training in internal medicine and pulmonary medicine at the University of California, San Francisco. He received his research training at the Cardiovascular Research Institute at UCSF, where he served on the faculty of the UCSF Department of Medicine.

Lota Zoth

Ms. Lota S. Zoth, CPA, is Independent Director of Spark Therapeutics, Inc. Ms. Zoth has served in senior financial roles in a variety of commercial-stage companies over a 30-year career, including serving as Chief Financial Officer for MedImmune before its acquisition by AstraZeneca in 2007. Prior to joining MedImmune in 2002, Ms. Zoth served as Senior Vice President, Corporate Controller and Principal Accounting Officer at PSINet Inc., Vice President, Corporate Controller and Chief Accounting Officer at Sodexho Marriott Services, Inc., Marriott International and PepsiCo, Inc. Ms. Zoth also served as an auditor at Ernst & Young, LLP and is a Certified Public Accountant. Ms. Zoth received a B.B.A. in accounting from Texas Tech University. She currently serves on the board of Orexigen Therapeutics, Inc., Aeras, Circassia Pharmaceuticals, PLC and NewLink Genetics Corporation.

Basic Compensation

Name Fiscal Year Total

Steven Altschuler

284,985

Katherine High

2,486,380

Jeffrey Marrazzo

4,910,290

Stephen Webster

2,043,290

John Furey

5,497,920

Lisa Dalton

--

Federico Mingozzi

--

Daniel Faga

2,208,290

Joseph La Barge

2,001,080

Lars Ekman

269,151

Anand Mehra

260,193

Vincent Milano

50,833

Robert Perez

--

Elliot Sigal

262,068

Lota Zoth

264,151
As Of  31 Dec 2017

Options Compensation